Mehta Kishan
CIK: 0001850520
Associated companies
Transaction History
| BHVN | ▼ Sell | Gift | 17,342 | $0 | 3/17/2026 | View on chart |
| BHVN | ▼ Sell | Gift | 17,342 | $0 | 3/17/2026 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 11,716 | $82K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 7,500 | $19K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 10,000 | $19K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 5,320 | $0 | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 937 | $0 | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,119 | $20K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 6,502 | $30K | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.